Niki BioSolutions, Inc.(NIKI)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.65
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NIKI

11/13/2026: NIKI (1-star) is currently NOT-A-BUY. Pass it for now.

Niki BioSolutions, Inc. is a small-cap, clinical-stage biotechnology company that focuses on repurposing existing drugs and developing biomarker-based diagnostics for oncology and infectious diseases. Its primary strengths are its lean operating model and specialized pipeline, which offer potential for lower development costs. The company's main investment story rests on the potential validation of its therapeutic candidates like SACT-1 and its diagnostic platform. However, the firm faces extreme risks, including persistent net losses, high clinical failure potential, and competition from well-funded industry giants. The stock is best suited for speculative investors who understand the binary, high-risk nature of clinical-stage biotech and should monitor cash runway and trial data closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company's lack of revenue and high execution risk makes it unsuitable for standard growth strategies.
Momentum investorWeak fitThe stock has demonstrated sustained downward momentum, failing to provide the positive signal required for this strategy.
Value investorWeak fitDeep-value metrics are not applicable to a pre-revenue clinical-stage entity with significant financial risk.
Dividend investorWeak fitThe company does not pay dividends and lacks the cash flow to support future payouts.
Low-risk investorWeak fitExtreme volatility and binary clinical-stage risks make this stock inappropriate for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock frequently experiences extreme intraday and historical price swings due to low float and clinical news dependence.
Valuation riskHighThe lack of underlying earnings or revenue makes traditional valuation models inapplicable.
Competition risk (Biopharma competition)HighThe company competes with global pharmaceutical giants that possess superior R&D funding.
Business qualityLowAs a pre-revenue, clinical-stage company, the business is in the earliest, highest-risk development phase.
Dividend incomeLow / noneThe company has no dividend policy and is not expected to pay one in the foreseeable future.
Execution riskHighFailure in clinical trials or inability to secure funding would directly threaten the firm's existence.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.15M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 20.2K shares
Beta -0.8
52 Weeks Range 1.42 - 17.20
Updated Date 11/14/2026
52 Weeks Range 1.42 - 17.20
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.81

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -86.07%
Avg. Invested days 6
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
NIKI receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft quantitative characteristics, and soft analyst coverage.

Company Fundamentals

★★★★★
NIKI has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, strong earnings growth (+68.1%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
NIKI's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is NIKI's strongest growth driver at +68.1% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+0.0%, slightly negative) and free-cash-flow growth (-54.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 0.6% (soft) and 18.2% of outstanding shares are publicly tradable (soft). Insider ownership of 47.53% supports management-shareholder alignment.

Top 5 Institutional Investors

Citadel Advisors Llc 0.08%
Advisor Group Holdings, Inc. 0.02%
SBI Securities Co Ltd 0.00%
Renaissance Technologies Corp 0.00%
Morgan Stanley - Brokerage Accounts 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
NIKI generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.96%

Quantitative Style Profile

★★★★★
NIKI has a relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Biopharmaceutical R&DDevelopment of therapeutics and diagnostics targeting oncology and infectious diseases.The company is currently burning cash to develop experimental drugs and has not yet established a profitable revenue stream.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3.06M
Price to Sales(TTM) 23.35
Enterprise Value 3.06M
Price to Sales(TTM) 23.35
Enterprise Value to Revenue 31.22
Enterprise Value to EBITDA -0.45
Shares Outstanding 2.94M
Shares Floating 535.93K
Shares Outstanding 2.94M
Shares Floating 535.93K
Percent Insiders 47.53
Percent Institutions 0.56

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.